Epimune GmbH and Tanner Pharma Group enter into Distribution Partnership for Latin America

Berlin, 27 January 2021 - Epimune GmbH, a molecular diagnostic company that develops, manufactures and commercializes in-vitro diagnostic tests for immune cell quantification from a drop of blood, announced today that it has entered into a license agreement with TannerLAC UK Limited ("TannerLAC"), a wholly owned subsidiary of Tanner Pharma Group for the i.Mune TBNK in-vitro diagnostic test in the Latin American region. TannerLAC provides pharmaceutical, biotech, and healthcare companies with a single-point partner for the commercialization of their products in challenging international markets.


Under the license agreement, TannerLAC will be responsible for product registrations, sales, and marketing activities in the Latin American region. First approvals are expected within the second half of 2021.


Carolina Cortez, EVP of TannerLAC, commented, “We are thrilled to partner with Epimune to be able to bring this revolutionary technology to Latin America to help immunodeficient patients have access to the i.Mune TBNK in-vitro diagnostic test that will facilitate early screening and monitoring which will help physicians make the best decisions when treating them.”


“We are very pleased to work with TannerLAC as a highly committed partner in making our i.Mune TBNK product widely available in Latin America,” said Uwe Staub, PhD, CEO of Epimune GmbH. “This partnership provides quick and professional access to the Latin American market which we consider very important for our product. We are looking forward to working closely with the TannerLAC team over the coming months. Together we will offer solutions to this market over the years ahead.”


About Epimune GmbH

Epimune is a molecular diagnostic company that develops and commercializes in vitro diagnostic (IVD) tests for molecular (i.e. epigenetic) immune cell quantification. The products are based on real-time PCR technology and allow accurate quantification of different immune cell subtypes from a drop of fresh, frozen or dried blood. Epimune’s first IVD product – i.Mune TBNK – allows quantification of CD3+, CD4+, CD8+ T-, B- and NK lymphocytes from as little as 40 μl of fresh blood or a dried blood spot (DBS). Epimune targets applications, where fresh blood samples are difficult or impossible to obtain. Lymphocyte enumeration can be used for follow-up and diagnostic evaluation of primary immunodeficiency, monitoring of HIV-positive patients, immune monitoring following immunosuppressive therapy for transplantation, autoimmunity and other immunological conditions, assessment of immune reconstitution post hematopoietic stem cell transplantation, early screening of gross quantitative anomalies in lymphocyte subsets in infections and malignancies and absolute quantification of circulating B cells for diagnosis of chronic lymphocytic leukemia (CLL) patients.


About Tanner Pharma Group

For over 18 years, Tanner Pharma Group has partnered with companies to provide turn-key solutions to increase access to medicines and other medical technology around the world. By partnering with Tanner Pharma Group, companies are able to focus on their primary markets while ensuring that patients and clinicians in international markets can receive their products through a strictly controlled channel. Tanner Pharma Group is headquartered in the United States with offices in the United Kingdom, Switzerland, Ireland and Brazil. Tanner Pharma Group has a global reach and provides international commercialization and patient access through licensing, managed access programs, global access programs and clinical trial services. For more information, please visit www.tannerpharma.com.


News Release for Download
Epimune_Tanner Pharma_PR_27 JAN 2021.pdf
Adobe Acrobat Document 139.7 KB